EFFECT OF AROMATASE INHIBITORS ON EARLY STAGE BREAST CANCER AND FREQUENCY OF JOINT PAIN SYMPTOMS IN POSTMENOPAUSAL WOMEN

Authors

  • Sadia Ikhlaque Sheikh Dow University of Health Sciences Karachi Pakistan
  • Fauzia Imtiaz Dow University of Health Sciences Karachi Pakistan
  • Shabnum Hasan Hamdard Medical University Karachi Pakistan
  • Zia Ikramuddin Dow University of Health Sciences Karachi Pakistan

Abstract

Objective: To find out the effect use of aromatase inhibitors on early stage breast cancer and the frequency of joint symptoms they developed.

Methods: This was a cross-sectional study on postmenopausal breast cancer women, who were receiving the different therapy for cancer. A questionnaire was used, comprises of demographic information and questions related to drug history and joint pain symptoms, and assessing the presence of joint symptoms at initial stage of cancer.

Results: Among 200 patients of this study, 93 (46.5%) reported having aromatase inhibitor-related joint pain and 89 (44.5%) with joint stiffness. Patients who received other medicines have less joint pain and stiffness (odds ratio [OR] _ 4.08, 95% CI, 1.20 to 10.43 and OR _ 4.46; 95% CI, 1.74 to 11.56, respectively).

Conclusion: Present study concluded that symptoms produced by aromatase inhibitor are more frequent in the female patients of breast cancer.

Keywords: Breast cancer, Aromatase inhibitor, Joint Symptoms, Postmenopausal women

Downloads

Published

28-04-2017

How to Cite

1.
Sheikh SI, Imtiaz F, Hasan S, Ikramuddin Z. EFFECT OF AROMATASE INHIBITORS ON EARLY STAGE BREAST CANCER AND FREQUENCY OF JOINT PAIN SYMPTOMS IN POSTMENOPAUSAL WOMEN. Pak J Pathol [Internet]. 2017 Apr. 28 [cited 2024 Apr. 19];28(1). Available from: https://pakjpath.com/index.php/Pak-J-Pathol/article/view/390

Issue

Vol. 28 No. 1 (2017)

Section

Articles

License

Copyright (c) 2017 Sadia Ikhlaque Sheikh, Fauzia Imtiaz, Shabnum Hasan, Zia Ikramuddin

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.